ALAlphabet Inc.
Institutional investor · Portfolio as of Q2 2025
Top Holdings36 positions
Stock | Shares | Value | Weight | Avg Buy | Est. P&L | Held | Conviction |
|---|---|---|---|---|---|---|---|
AST SPACEMOBILE INC | 8.9M | $417.9M | 19.6% | $24.06 | +105.15% | 2 qtrssince 2025-Q1 | Unchanged 0 |
ARM Holdings PLC Sponsored ADR | 2M | $317.1M | 14.9% | $53.52 | +209.16% | 8 qtrssince 2023-Q3 | Unchanged 0 |
FRESHWORKS INC | 16.2M | $241.6M | 11.3% | $15.72 | -5.74% | 11 qtrssince 2022-Q4 | Unchanged 0 |
PLANET LABS PBC | 31.9M | $194.9M | 9.1% | $4.35 | +39.54% | 11 qtrssince 2022-Q4 | Unchanged 0 |
REVOLUTION MEDICINES INC | 4.1M | $152.1M | 7.1% | $28.69 | +28.65% | 7 qtrssince 2023-Q4 | Unchanged 0 |
METSERA INC | 5M | $141.2M | 6.6% | — | — | 2 qtrssince 2025-Q1 | Unchanged 0 |
VERVE THERAPEUTICS INC | 12.2M | $136.7M | 6.4% | — | — | 11 qtrssince 2022-Q4 | Decreased 0 |
GITLAB INC | 2.7M | $122.9M | 5.8% | $54.31 | -16.88% | 11 qtrssince 2022-Q4 | Unchanged 0 |
Tempus AI, Inc. Class A | 1.6M | $98.6M | 4.6% | $35.00 | +90.06% | 5 qtrssince 2024-Q2 | Unchanged 0 |
DEXCOM INC | 1M | $90.5M | 4.2% | $122.16 | -29.33% | 11 qtrssince 2022-Q4 | Unchanged 0 |
UIPATH INC | 7M | $90M | 4.2% | $12.71 | +0.16% | 11 qtrssince 2022-Q4 | Unchanged 0 |
PRIME MEDICINE INC | 15.1M | $37.2M | 1.7% | $16.12 | -84.99% | 11 qtrssince 2022-Q4 | Unchanged 0 |
MAZE THERAPEUTICS INC | 2.4M | $29.6M | 1.4% | $11.42 | +6.22% | 2 qtrssince 2025-Q1 | Unchanged 0 |
OSCAR HEALTH INC - CLASS A | 481,988 | $10.3M | 0.5% | $2.46 | +729.67% | 11 qtrssince 2022-Q4 | Unchanged 0 |
SANA BIOTECHNOLOGY INC | 2.8M | $7.7M | 0.4% | $3.95 | -28.86% | 11 qtrssince 2022-Q4 | Unchanged 0 |
MONTE ROSA THERAPEUTICS INC | 1.5M | $6.6M | 0.3% | $7.61 | -39.55% | 11 qtrssince 2022-Q4 | Unchanged 0 |
VERA THERAPEUTICS INC | 241,264 | $5.7M | 0.3% | $19.35 | +17.05% | 11 qtrssince 2022-Q4 | Unchanged 0 |
BEAM THERAPEUTICS INC | 321,604 | $5.5M | 0.3% | $39.11 | -57.04% | 11 qtrssince 2022-Q4 | Unchanged 0 |
RELAY THERAPEUTICS INC | 1.6M | $5.4M | 0.3% | $14.94 | -77.91% | 11 qtrssince 2022-Q4 | Unchanged 0 |
Dianthus Therapeutics, Inc. | 208,697 | $3.9M | 0.2% | $13.67 | +28.97% | 8 qtrssince 2023-Q3 | Unchanged 0 |
Alphabet Inc. manages $2.1B across 36 positions as of Q2 2025. Top holdings: ASTS (19.6%), ARM (14.9%), FRSH (11.3%). Fund DNA: Concentrated Value. HoldingsIntel Rating: 1.5/5.0.
Exited 4, trimmed 2. No standout high-conviction moves this quarter. Portfolio: $2.1B across 36 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
No active accumulation streaks detected for this filer.
Streaks require 2+ consecutive quarters of increased positions in the most recent period.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer